Anti-CRISPR Inhibitors for Spatiotemporal Cas9 Activity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CRISPR-Cas9 systems lack predictable control and robust inhibition of Cas9 gene editing activity, leading to unintended DNA cleavage or binding, which poses safety risks in therapeutic and research applications.
Innovation Solution
Development of Type II-C Cas9 anti-CRISPR (Acr) inhibitors that bind specifically to Cas9 proteins, providing precise control over gene editing activity, reducing off-target events, and preventing unwanted DNA cleavage or binding.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If CRISPR-Cas systems are used for gene editing, then precision and efficiency of gene editing are improved, but off-target effects and unintended genetic modifications occur
Solution Approach 1:
The patent introduces anti-CRISPR proteins (Acr proteins) as intermediary molecules that specifically bind to and inhibit CRISPR-Cas systems. These Acr proteins act as mediators that can be precisely controlled to prevent off-target effects while allowing on-target gene editing to proceed when needed, thus resolving the contradiction between editing precision and harmful off-target effects
Solution Approach 2:
The patent utilizes parameter changes by controlling the expression levels, binding affinities, and activity states of CRISPR-Cas systems through regulatory elements and inducible systems. By dynamically adjusting these parameters, the system achieves high precision gene editing when activated while minimizing off-target effects during inactive states
2Reliability
If CRISPR-Cas systems are used for therapeutic applications, then treatment effectiveness is improved, but immune responses and safety concerns arise
Solution Approach 1:
Anti-CRISPR proteins serve as protective intermediaries that shield therapeutic CRISPR-Cas systems from unwanted immune recognition and activation. By controlling the interaction between Acr proteins and CRISPR-Cas components, the patent reduces immune responses while maintaining treatment effectiveness in targeted applications
Solution Approach 2:
The patent converts the potential harm of immune responses by using Acr proteins to modulate the immune system's reaction to CRISPR-Cas therapy. The immune system's natural surveillance mechanisms are redirected to favorably recognize and tolerate the therapeutic system while still providing protection against actual threats
3Ease of operation
If CRISPR-Cas systems are used for gene regulation, then control over gene expression is improved, but unintended genetic modifications and genomic instability occur
Solution Approach 1:
The patent employs dynamic control mechanisms where Acr proteins and CRISPR-Cas systems interact in a controllable, reversible manner. This dynamic system allows precise temporal and spatial control of gene expression regulation while preventing unintended genomic modifications through controlled inhibition and activation cycles
Solution Approach 2:
The patent utilizes periodic action by implementing cyclic activation and inhibition of CRISPR-Cas systems through regulated expression of Acr proteins. This periodic control pattern allows gene expression to be modulated in controlled waves, achieving ease of operation while maintaining genomic stability through rest periods that prevent continuous stress on the genome
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The Acr inhibitors enable safe and precise spatial or temporal control of Cas9 activity, minimizing off-target effects and enhancing the efficacy and safety of gene editing therapies and research.
Implementation Method 1
The anti-CRISPR (Acr) proteins are bacterial proteins that have evolved to inhibit CRISPR-Cas systems
Implementation Method 2
A guide RNA (crRNA or sgRNA) is used to direct the nuclease to a specific target sequence
Implementation Method 3
The CRISPR-Cas system uses a guide RNA (crRNA or sgRNA) to direct the nuclease to a specific target sequence, where it creates double-strand breaks
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is related to the field of CRISPR-Cas9 gene editing platforms. In particular, the present invention has identified Type II-C Cas9 anti-CRISPR (Acr) inhibitors that control Cas9 gene editing activity. Co-administration of such Acr inhibitors may provide an advantageous adjunct in permitting safe and practical biological therapeutics through spatial or temporal control of Cas9 activity; controlling Cas9-based gene drives in wild populations to reduce the ecological consequences of such forced inheritance schemes; and contributing to general research into various biotechnological, agricultural, and medical applications of gene editing technologies.